JP2010518158A - 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法 - Google Patents

成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法 Download PDF

Info

Publication number
JP2010518158A
JP2010518158A JP2009549593A JP2009549593A JP2010518158A JP 2010518158 A JP2010518158 A JP 2010518158A JP 2009549593 A JP2009549593 A JP 2009549593A JP 2009549593 A JP2009549593 A JP 2009549593A JP 2010518158 A JP2010518158 A JP 2010518158A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hetaryl
growth hormone
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518158A5 (enExample
Inventor
ジェイ． ポルビーノ，ウィリアムズ
Original Assignee
ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド filed Critical ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド
Publication of JP2010518158A publication Critical patent/JP2010518158A/ja
Publication of JP2010518158A5 publication Critical patent/JP2010518158A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2009549593A 2007-02-13 2008-02-08 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法 Pending JP2010518158A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90160907P 2007-02-13 2007-02-13
PCT/US2008/001748 WO2008100448A2 (en) 2007-02-13 2008-02-08 Method of treating cell proliferative disorders using growth hormone secretagogues

Publications (2)

Publication Number Publication Date
JP2010518158A true JP2010518158A (ja) 2010-05-27
JP2010518158A5 JP2010518158A5 (enExample) 2011-03-31

Family

ID=39690677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549593A Pending JP2010518158A (ja) 2007-02-13 2008-02-08 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法

Country Status (12)

Country Link
US (1) US20080207640A1 (enExample)
EP (1) EP2134341B1 (enExample)
JP (1) JP2010518158A (enExample)
KR (1) KR20090112720A (enExample)
CN (1) CN101686966A (enExample)
AU (1) AU2008216789A1 (enExample)
CA (1) CA2677813A1 (enExample)
EA (1) EA200970764A1 (enExample)
IL (1) IL200367A0 (enExample)
MX (1) MX2009008561A (enExample)
TW (1) TWI450719B (enExample)
WO (1) WO2008100448A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526695A (ja) * 2014-09-04 2017-09-14 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011105611A1 (ja) * 2010-02-26 2013-06-20 ラクオリア創薬株式会社 悪液質を治療するためのグレリン受容体作動物質
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CN111557432B (zh) 2013-02-08 2023-08-04 通用磨坊公司 低钠食品
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6274584B1 (en) * 1996-07-22 2001-08-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010041720A1 (en) * 1999-11-10 2001-11-15 Michael Ankersen Compound with growth hormone releasing properties
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP2003535144A (ja) * 2000-06-07 2003-11-25 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 多能性造血幹細胞の流動を刺激するヒト成長ホルモン
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179597A1 (en) * 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
AU715856B2 (en) * 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566334B1 (en) * 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6286927B1 (en) * 1997-12-25 2001-09-11 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6494563B2 (en) * 1997-12-25 2002-12-17 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6124263A (en) 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
EP1159964B1 (en) * 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
JP2005511475A (ja) * 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN101657436A (zh) * 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274584B1 (en) * 1996-07-22 2001-08-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010041720A1 (en) * 1999-11-10 2001-11-15 Michael Ankersen Compound with growth hormone releasing properties
JP2003535144A (ja) * 2000-06-07 2003-11-25 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 多能性造血幹細胞の流動を刺激するヒト成長ホルモン

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6012066450; Ｂａｘｔｅｒ　ＲＣ．: 'Ｓｉｇｎａｌｌｉｎｇ　ｐａｔｈｗａｙｓ　ｉｎｖｏｌｖｅｄ　ｉｎ　ａｎｔｉｐｒｏｌｉｆｅｒａｔｉｖｅ　ｅｆｆｅｃｔｓ　ｏｆ　ＩＧＦＢＰ-３：　ａ　ｒｅｖｉｅｗ．' Ｍｏｌ　Ｐａｔｈｏｌ． Ｖｏｌ．５４　Ｎｏ．３, 200106, ｐｐ．１４５-１４８ *
JPN6012066452; Ｎｅａｒｙ　ＮＭ　ｅｔ　ａｌ．: 'Ｇｈｒｅｌｉｎ　ｉｎｃｒｅａｓｅｓ　ｅｎｅｒｇｙ　ｉｎｔａｋｅ　ｉｎ　ｃａｎｃｅｒ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｉｍｐａｉｒｅｄ　ａｐｐｅｔｉｔｅ：　ａｃｕｔｅ，　ｒａｎｄｏｍｉｚｅｄ，　ｐｌａｃｅｂ' Ｊ　Ｃｌｉｎ　Ｅｎｄｏｃｒｉｎｏｌ　Ｍｅｔａｂ． Ｖｏｌ．８９　Ｎｏ．６, 200406, ｐｐ．２８３２-２８３６ *
JPN6012066455; Ｐｉｎｅｓ　ＳＨ: 'Ａ　Ｐｒａｃｔｉｃａｌ　Ｓｙｎｔｈｅｓｉｓ　ｏｆ　ｔｈｅ　Ｐｓｅｕｄｏｔｒｉｐｅｐｔｉｄｅ　ＲＣ-１２９１' Ｏｒｇ．　Ｐｒｏｃｅｓｓ　Ｒｅｓ．　Ｄｅｖ．， Ｖｏｌ．１０　Ｎｏ．２, 2006, ｐｐ．３３９-３４５ *
JPN6014002496; Ｋｕｍｏｒ　Ｋ　ａｎｄ　Ｐｏｌｖｉｎｏ　Ｗ: 'Ｂｉｏｌｏｇｉｃ　ａｃｔｉｖｉｔｙ　ｏｆ　ＲＣ-１２９１，　ａ　ｎｏｖｅｌ　ｏｒａｌ　ｇｈｒｅｌｉｎ　ｍｉｍｅｔｉｃ　ｆｏｒ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｃａｎｃｅｒ　ａｎｏｒｅｘｉａ／ｃａｃｈ' Ｓｕｐｐｏｒｔ　Ｃａｒｅ　Ｃａｎｃｅｒ Ｖｏｌ．１４, 2006, ｐ．５９３ *
JPN6014002500; Ｈａｎａｄａ　Ｔ　ｅｔ　ａｌ．: 'Ａｎｔｉ-ｃａｃｈｅｃｔｉｃ　ｅｆｆｅｃｔ　ｏｆ　ｇｈｒｅｌｉｎ　ｉｎ　ｎｕｄｅ　ｍｉｃｅ　ｂｅａｒｉｎｇ　ｈｕｍａｎ　ｍｅｌａｎｏｍａ　ｃｅｌｌｓ．' Ｂｉｏｃｈｅｍ　Ｂｉｏｐｈｙｓ　Ｒｅｓ　Ｃｏｍｍｕｎ． Ｖｏｌ．３０１　Ｎｏ．２, 20030207, ｐｐ．２７５-２７９ *
JPN6014002501; 塚田　俊彦: '増殖因子、サイトカインによるがん病態の修飾に関する研究' 厚生労働省がん研究助成金による研究報告集 平成１３年度, 200209, ｐｐ．１３８-１４３ *
JPN6014002504; Ａｋａｍｉｚｕ　Ｔ　ａｎｄ　Ｋａｎｇａｗａ　Ｋ: 'Ｔｒａｎｓｌａｔｉｏｎａｌ　ｒｅｓｅａｒｃｈ　ｏｎ　ｔｈｅ　ｃｌｉｎｉｃａｌ　ａｐｐｌｉｃａｔｉｏｎｓ　ｏｆ　ｇｈｒｅｌｉｎ．' Ｅｎｄｏｃｒ　Ｊ． Ｖｏｌ．５３　Ｎｏ．５, 20060728, ｐｐ．５８５-５９１ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526695A (ja) * 2014-09-04 2017-09-14 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療
JP2018154655A (ja) * 2014-09-04 2018-10-04 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療
JP2021080281A (ja) * 2014-09-04 2021-05-27 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療
JP7044918B2 (ja) 2014-09-04 2022-03-30 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療

Also Published As

Publication number Publication date
EA200970764A1 (ru) 2010-04-30
CA2677813A1 (en) 2008-08-21
EP2134341A4 (en) 2011-08-17
EP2134341A2 (en) 2009-12-23
AU2008216789A1 (en) 2008-08-21
TW200914019A (en) 2009-04-01
EP2134341B1 (en) 2015-06-17
KR20090112720A (ko) 2009-10-28
TWI450719B (zh) 2014-09-01
US20080207640A1 (en) 2008-08-28
WO2008100448A2 (en) 2008-08-21
MX2009008561A (es) 2010-01-15
CN101686966A (zh) 2010-03-31
IL200367A0 (en) 2010-04-29
WO2008100448A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
JP2010518158A (ja) 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
JP6625690B2 (ja) Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
EP2670733B1 (en) N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
TWI674111B (zh) 藥物傳送結合物、治療由表現ｐｓｍａ之細胞所引起疾病之方法
CA2897150C (en) Methods for reducing cellular proliferation and treating certain diseases
CN101678064B (zh) 使用生长激素促泌素治疗或预防呕吐之方法
WO2022183993A1 (zh) 一种前列腺特异性膜抗原靶向化合物及其制备方法和应用
US11739064B2 (en) HDAC inhibitors and therapeutic methods using the same
CA3142960A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
WO2011106639A1 (en) Psma binding ligand-linker conjugates and methods for using
CZ293682B6 (cs) Peptid, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
JP2001517250A (ja) ナフタレンスルホン酸誘導体を含有する相乗作用抗腫瘍組成物
WO2016049313A1 (en) Methods of treating cancer with tubulysin conjugates
JP2013503888A (ja) 癌を治療するための化合物および組成物
KR20060124610A (ko) 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
KR100776184B1 (ko) 치환된 아크릴로일 디스타마이신 유도체를 포함하는, 고수준의 글루타티온과 관련된 종양 치료용 약제학적 조성물
US20250099414A1 (en) Compositions and methods for treating triple-negative breast cancer
HK40118231A (en) Psma binding ligand-linker conjugates and methods for using
MXPA06004999A (en) Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130405

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140826